Intravenous Nalbuphine Versus Lidocaine for Prevention of Propofol Injection Pain

Trial statusNot yet recruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
Age18-60
SponsorHayatabad Medical Complex

About this trial

Propofol is a commonly used intravenous anesthetic agent, but its administration is frequently associated with injection pain, causing patient discomfort and agitation. Various pharmacological agents have been used to reduce this pain, including nalbuphine and lidocaine; however, results from previous studies remain conflicting. This randomized clinical trial aims to compare the effectiveness of intravenous nalbuphine versus intravenous lidocaine in reducing the frequency of propofol-induced injection pain in patients undergoing elective general surgery procedures.

Eligibility criteria

Qualifiers

Age 18-60 years

Either male or female

ASA physical status I or II

Scheduled for elective general surgery under general anesthesia using propofol

Disqualifiers

Known hypersensitivity to propofol, nalbuphine, or lidocaine

Emergency surgery

Use of analgesics prior to surgery

Pregnant women

Trial design

Treatments tested in this trial

  • Nalbuphine
  • Lidocaine

Treatment groups

92 Participants
are divided into 2 treatment groups

Locations

This trial has no locations

Sponsors and collaborators